SoftBank-Backed Genetic Testing Invitae's Descent From $7B Valuation to Near-Bankruptcy
SoftBank-Backed Genetic Testing Invitae's Descent From $7B Valuation to Near-Bankruptcy
Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks.
據報道，由軟銀集團（場外交易代碼：SFTBY）（場外交易代碼：SFTBF）支持的Invitae公司（紐約證券交易所代碼：NVTA）將在未來幾周內處於申請破產的邊緣。
The San Francisco-based medical genetics company, grappling with a substantial $1.5 billion debt burden, is enlisting the expertise of restructuring advisers from FTI Consulting and legal counsel from Kirkland & Ellis to navigate its financial challenges.
這家總部位於舊金山的醫學遺傳學公司正在努力應對15億美元的巨額債務負擔，正在尋求FTI Consulting的重組顧問和Kirkland & Ellis的法律顧問的專業知識來應對其財務挑戰。
Amidst this financial turmoil, Invitae is actively exploring various strategic options, and bankruptcy is a prominent consideration.
在這場金融動盪中，Invitae正在積極探索各種戰略選擇，破產是一個重要的考慮因素。
The company, known for its aggressive acquisition approach in recent years, has initiated the shedding of assets and cost-cutting measures to address its precarious financial situation, the Wall Street Journal noted.
《華爾街日報》指出，該公司近年來以其激進的收購方針而聞名，已開始削減資產和削減成本的措施，以解決其不穩定的財務狀況。
Notably, the downward trajectory of Invitae mirrors the struggles faced by its industry counterpart, 23andMe Holdings Co (NASDAQ:ME), a genetic testing company.
值得注意的是，Invitae的下行軌跡反映了其行業同行、基因檢測公司23andMe Holdings Co（納斯達克股票代碼：ME）所面臨的困境。
23andMe's market cap plummeted from $6 billion in 2021 to a mere $332 million, reflecting the challenges within the genetic testing sector.
23andMe的市值從2021年的60億美元暴跌至僅3.32億美元，這反映了基因檢測領域的挑戰。
Invitae's stock, which once soared above $50, dramatically declined. The company's market cap, previously exceeding $7 billion, has dwindled significantly over the past 12 months, experiencing an 82% loss in value.
Invitae的股票曾飆升至50美元以上，但大幅下跌。該公司的市值此前已超過70億美元，在過去12個月中大幅下降，市值損失了82％。
Having invested $1.2 billion in convertible debt in 2021 to support Invitae's asset acquisition plans, SoftBank remains a stakeholder in the beleaguered company.
軟銀在2021年投資了12億美元的可轉換債券，以支持Invitae的資產收購計劃，但它仍然是這家陷入困境的公司的利益相關者。
In January, Invitae sold its non-invasive prenatal and carrier screening business to Natera Inc (NASDAQ:NTRA) for $10 million. The transaction includes $42.5 million in potential milestone payments, including cash and litigation-related credits.
1月，Invitae以1000萬美元的價格將其非侵入性產前和攜帶者篩查業務出售給了Natera Inc（納斯達克股票代碼：NTRA）。該交易包括4,250萬美元的潛在里程碑付款，包括現金和訴訟相關信貸。
In December 2023, Invitae divested Ciitizen's assets and announced strategic cost cuts, including workforce reduction and other operating expense reductions, with an anticipated cash savings of approximately $90 million-100 million on an annualized basis.
2023年12月，Invitae剝離了Ciitizen的資產，並宣佈了戰略成本削減，包括裁員和其他運營費用削減，預計按年計算可節省約9000萬至1億美元的現金。
Price Action: NVTA shares are down 68.80% at $0.122 on the last check Monday.
價格走勢：週一的最後一次支票中，NVTA股價下跌68.80％，至0.122美元。
Photo via Wikimedia Commons
照片來自維基共享資源
譯文內容由第三人軟體翻譯。